‘Quiet Giant’ Biocon Sets Out Vision For Biosimilars
Advanced Markets Chief Matt Erick Discusses Upcoming Milestones For Biocon Biologics
Biocon Biologics chief commercial officer for advanced markets Matt Erick says the firm is a “quiet giant” in the biosimilars space, but speaks up about the firm’s plans to grow its business in Europe, explore in-licensing as well as in-house development, and capitalize on the upcoming loss of exclusivity for Stelara in the US.
